Renal Protection in the Diabetes Patient (Diabetes Simplified - Practical Recommendations to Improve Diabetes Care)
People with diabetes are at high risk of developing chronic kidney disease (CKD). RAAS inhibition with an ACE inhibitor or ARB have been a standard of care for most of these patients. Primary care clinicians are encouraged to use the latest evidence from antihyperglycemic agent trials demonstrating an improvement in CKD outcomes in managing their patients with type 2 diabetes.
This program is developed in collaboration with Partners in Progressive Medical Education (PPME), and endorsed by Diabetes Canada.This program has received an educational grant or in-kind support from Abbott Diabetes Care, Astra Zeneca, Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc., Janssen, Novo Nordisk and Sanofi.
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits. Cert+ Program ID#: 193524
Louis Girard, MD, MBT, FRCPC
Maureen Clement, MD, CCFP
James Kim, MBBCh, PgDip
Peter J. Lin, MD, CCFP
- Review the prevalence and impact of chronic kidney disease (CKD) in persons with diabetes
- Review guidelines for the assessment of renal function in type 2 diabetes
- Apply guidelines for the management of CKD and diabetes that have been shown to improve renal outcomes